UCL Queen Square Institute of Neurology


QS MS Centre: Vision Statement

Vision Statement

The Queen Square Multiple Sclerosis (MS) Centre will be a national and international leading centre of MS research, working collaboratively to expedite the translation of new insights from basic disease mechanisms into experimental medicine studies, clinical trials, and novel disease modifying and symptomatic treatments and rehabilitation techniques, for the benefit of people with MS.

Our vision for MS reflects the UCL/UCLH Biomedical Research Centre’s vision “to be a global leading centre in Experimental Medicine accelerating the development of novel therapeutics, diagnostics, and devices for patient benefit.”.

Strategic Approach 

  1. The Centre has been constituted with international leaders in the fields of experimental neuroinflammation, imaging measures of MS pathology and pathogenic mechanisms, proof-of-concept clinical trials, trial design, centralised image analysis in trials, and symptomatic treatment including rehabilitation.
  2. The Centre will promote fundamental advances in our basic research laboratories, examine the new knowledge in our research clinics, and test promising new treatments, for the benefit of people with MS.
  3. The Centre will identify priorities and strategies for recruitment of the most outstanding researchers and novel technologies to fully achieve our vision.
  4. The Centre will promote collaboration between research and clinical service at Queen Square, UCL and UCLH,  to enhance the excellence of both for the benefit of people with MS.
  5. The Centre will collaborate with other leading MS research and clinical centres in the UK and internationally to enhance quality and productivity.


  1. Use accurate experimental models of MS to understand why new lesions form and grow, and how they cause symptoms, in order to devise novel strategies for treating MS, including neuroprotection.
  2. Elucidate pathogenic mechanisms and identify novel treatment strategies through expert study of post mortem pathology and in vivo tissue fluid immunological and other biomarkers in MS.
  3. Develop new imaging techniques for accurate and timely MS diagnosis and to understand MS pathophysiology and expedite effective new disease modifying treatments.
  4. Perform central MRI analysis in multicentre trials of potential new treatments for MS.
  5. Develop new clinical trial design and analysis strategies and associated statistical methodology.
  6. Test promising new therapies to modify the course of MS, with a focus on neuroprotection and repair in order to prevent and reverse disability in both early and late disease.
  7. Identify new strategies for patient support, symptomatic treatment and rehabilitation, in order to reduce disability and improve well-being.